Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cohort study of cardiovascular event risk with abaloparatide vs teriparatide in osteoporosis
jRCT2031250561Recruiting
- Sponsor
- Teijin Pharma
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label trial of abaloparatide and teriparatide in osteoporosis (2 cohorts), sponsored by Teijin Pharma. Primary endpoint: Composite cardiovascular events. Started Jan 2023; status: recruiting.
02
Drugs
abaloparatideteriparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on jRCT2031250561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250561.